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Urokinase-Type Plasminogen Activator to Prevent Haze
after Photorefractive Keratectomy, and Pregnancy as a
Risk Factor for Haze in Rabbits
Adrienne Csutak,1 David M. Silver,1,2 Jo´zsef To¨zse´r,3 Ziad Hassan,1 and Andra´s Berta1
PURPOSE. To observe the effect of urokinase-type plasminogen
activator (uPA) on the development of subepithelial haze after
photorefractive keratectomy (PRK) and to assess pregnancy as
a risk factor for haze.
METHODS. In 30 rabbits, both eyes of 27 were subjected to PRK
and both eyes of 3 served as the nonsurgical control. In the first
part of the experiment, for 7 days after PRK, three rabbits (one
was pregnant) received aprotinin in one eye and no aprotinin
in the contralateral eye. uPA activity was measured by a spec-
trophotometric method from tear samples in these eyes. In the
second part, for 5 days after PRK, 24 rabbits (8 were pregnant)
were treated with uPA in one eye and no uPA in the contralat-
eral eye. Haze grading was performed according to the system
of Hanna.
RESULTS. In the first experiment, the aprotinin-treated eyes and
the aprotinin-untreated eye of the pregnant rabbit showed
development of haze. In the second, there were clear corneas
in 24 of 24 uPA-treated eyes and in 15 of 24 uPA-untreated
eyes. Post-PRK haze formed in 9 of 24 uPA-untreated eyes (7 of
the 9 haze observations in pregnant rabbits). Within the uPA-
untreated group, haze formed in corneas of 7 of 8 pregnant
versus 2 of 16 nonpregnant rabbits. There was a strong asso-
ciation between the uPA treatment and clear corneas (P 
0.003) and between pregnancy and haze (P  0.002).
CONCLUSIONS. The present results suggest that pregnancy is a
risk factor for post-PRK haze in untreated rabbit eyes and that
uPA is effective in preventing the occurrence of haze. (Invest
Ophthalmol Vis Sci. 2004;45:1329 –1333) DOI:10.1167/
iovs.03-0881
Photorefractive keratectomy (PRK) involves removal of thecorneal epithelium and application of an excimer laser to
the Bowman layer and the anterior stroma. The resultant re-
shaping of the cornea alters its optical power (approximately
10 m ablation depth corrects 1 D of myopia). Re-epithelial-
ization of the cornea occurs usually within 3 to 5 days after
surgery. Postsurgical complications of PRK include excessive
myopic regression and disturbances in corneal transparency.
When post-PRK subepithelial corneal haze or cloudiness
occurs, it is observed after a few weeks to a few months after
surgery. Its duration can be from weeks to months, with some
occurrences lasting more than a year.1 It can be mild to se-
vere.2 Even in clear corneas, belated changes in the corneal
stroma have been observed 8 to 43 months after PRK.2 There
is a wide variability in the reported prevalence of haze.3,4 A
recent study5 found an 8% occurrence of mild haze after PRK.
Another study found a 29% incidence among brown-eyed indi-
viduals and a 5% incidence among blue-eyed subjects.6 Post-
PRK haze is not correlated with the patient’s age7 but haze
appears to be highest in the patient with high myopia who is
undergoing PRK with a greater ablation depth.8 The degree of
patient satisfaction with PRK is negatively correlated with the
degree of corneal haze.9
Urokinase-type plasminogen activator (uPA) is a serine pro-
tease originating in conjunctival and corneal epithelial
cells10–14 and is a normal component of tear fluid.15 In previ-
ous work on humans,5 levels of uPA activity in tear fluid were
measured during corneal re-epithelialization after excimer laser
PRK. Tear samples were collected with glass capillaries from
77 eyes of 42 human patients before and during the 5-day
period after PRK. In 20 patients, the contralateral eye was
similarly sampled as a control. The uPA activity in the tear
samples was measured by a spectrophotometric method using
human plasminogen and chromogenic peptide substrate
S-2251. The tear uPA activity was lower immediately after PRK,
compared with preoperative values. In 71 human eyes with
normal wound healing (clear corneas), uPA activity was signif-
icantly elevated above the preoperative level on the third
postoperative day and then returned to the preoperative level
by the fifth postoperative day. In contrast, tear uPA activity
remained low through the third postoperative day in the six
human eyes in which haze eventually developed after 3 to 6
months. In previous human16 and rabbit17 studies, post-PRK
corneal haze was found to be greater in eyes treated with
aprotinin, a serine protease inhibitor.
Profound changes in the fibrinolytic system have been ob-
served to occur during pregnancy, resulting from increased
plasma concentrations of plasminogen activators and their in-
hibitors compared with nonpregnant levels.18,19 The uPA in-
hibitory activity of pregnancy plasma continues from preg-
nancy through 1 to 2 days postpartum.19,20 Natural alteration
of the plasminogen activator system attending pregnancy sug-
gests the possibility that pregnancy may be a risk factor for
altering the plasminogen cascade in corneal wound healing.
One purpose of the present work was to explore this possibil-
ity.
In the previous human5 studies, low levels of uPA activity,
extending a few days beyond the surgery, correlate with the
later development of corneal healing abnormality (haze). This
suggests the possibility that replacing (eye drops) uPA may
serve as a therapeutic measure for reducing or preventing the
occurrence of haze. A second purpose of the present work was
to examine the effect on haze formation of providing uPA in
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the form of eye drops after PRK surgery in pregnant and
nonpregnant rabbits.
METHODS
Thirty healthy New Zealand rabbits (3.0–3.5kg) were included in the
study. PRK surgery was performed on both eyes of 27 rabbits, of which
9 were pregnant. Three rabbits underwent no surgery and served as
the control. The distribution of rabbit eyes into various groups is
shown in Table 1. Animals were handled and treated in compliance
with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
All PRK surgeries were identical: 6-D spherical correction with a
6.0-mm ablation zone and an ablation depth of 68 m with an excimer
laser (193 nm Keratom II ArF; Schwind, Kleinostheim, Germany),
performed by the same surgeon at Vital-Laser LLC, Department of
Ophthalmology, University of Debrecen Medical and Health Science
Center Faculty of Medicine. De-epithelialization was performed with a
blunt keratome blade knife after epithelial marking with a 6.0- to
6.5-mm Hoffer trephine. The epithelium was scraped gently from
periphery to center. Residual epithelial debris was removed with a
sterile microsponge. Topical anesthetic (0.4% oxybuprocaine hydro-
chloride) eye drops were administered twice before the surgery. Gen-
eral anesthesia was accomplished by intravenous injection of ketamine-
xylazine at a ratio of 60 to 5 mg/kg. The PRK surgeries were performed
on the morning of day 1.
The postoperative treatment of both eyes included antibiotic eye
drops (Ciloxan; Alcon, Ft. Worth, TX), administered from morning to
early evening, 12 times (hourly) on day 1 and 5 times (every 2 hours)
on five additional days (postoperative days 2 to 5 and 7). After the
seventh day, a corticosteroid (fluorometholone; Flucon; Alcon) and
artificial tears (Tears Naturale; Alcon) were also administered from
morning to early evening, five times daily (every 2 hours) during the
first postoperative month, reduced to four times daily (every 3 hours)
for the second month and to three times daily (every 4 hours) for the
third month.
Six eyes of three rabbits underwent no surgery and were labeled
nonsurgical control eyes. The six nonsurgical control eyes received
antibiotic, corticosteroid, and artificial tears on the same schedule and
with the same procedure as described for the surgical eyes. Because
the antibiotic, corticosteroid, and artificial tears regimen is considered
to be standard postoperative care for corneal surgery, these elements
were not separately controlled for in this study.
One eye of each of three surgical rabbits received 1 drop of 10,000
kIU/mL aprotinin (Gordox, Richter Gedeon Rt., Budapest, Hungary).
The aprotinin was administered during the morning through early
evening, 12 times (hourly) on day 1 and 5 times (every 2 hours) on
postoperative days 2 to 5 and 7. This was designated the aprotinin-
treated group.
One eye of each of 24 surgical rabbits was treated with 1 drop of
the antibiotic containing 50 IU/mL uPA (Ukidan, Serono SpA; Unter-
schleissheim, Germany) from morning to early evening, 12 times
(hourly) on day 1 and 5 times (every 2 hours) on postoperative days 2
to 5 and 7. This was designated the uPA-treated group.
The three contralateral surgical eyes in the aprotinin-treated group
(labeled aprotinin-untreated control) and the 24 contralateral surgical
eyes in the uPA-treated group (labeled uPA-untreated control) were
treated with the same antibiotic, corticosteroid, and artificial tear eye
drop regimen after PRK, but without aprotinin or uPA, respectively.
For the three aprotinin-treated and three aprotinin-untreated con-
trol eyes, tear samples for uPA activity analyses were obtained on the
day before PRK surgery (day 0). Tear samples were collected within
minutes after PRK (day 1), before treatment with any eye drops. Daily,
on postoperative days 2 to 5, on postoperative day 7, and every fourth
day thereafter for 3 months, tears were sampled in the morning before
the administration of eye drops on the given day. Tear samples were
also collected from the nonsurgical control eyes on the same schedule
and with the same procedure as described for the surgical eyes.
Samples consisted of tears collected with glass capillaries21,22 using
intramuscular injection of pilocarpine hydrochloride (5 mg/kg) for
stimulation. Tears were taken from the lower tear meniscus, and care
was taken not to touch the conjunctiva. The same collection method
was used throughout the study. The duration of the sampling time was
recorded, and the secretion rate was calculated in microliters per
minute, dividing the obtained tear volume by the time of sample
collection. Samples used in this investigation had secretion rates of 10
to 50 L/min. Samples were centrifuged (1800 rpm) for 8 to 10
minutes right after sample collection, and supernatants were deep
frozen at 80°C and were thawed only once for measurements.
The uPA activity was measured in the tear samples by a spectro-
photometric method using human plasminogen and a plasmin-specific
chromogenic peptide substrate, D-valyl-L-leucyl-L-lysyl-p-nitroanilide (S-
2251).23 This assay is sensitive predominantly to uPA.21 The plasmin-
ogen and the S-2251 were purchased from Chromogenix (Milan, Italy).
The uPA standard was purchased from Choay (Paris, France). This
assay is suitable for measuring plasmin activity but can also be used for
determining uPA activity by adding plasminogen to the reagents. The
uPA activity was measured as described by Shimada et al.23 with the
modifications reported by Csutak et al.5 To˜zse´r et al.,21 and To˜zse´r and
Berta.24
All rabbits received follow-up examinations at 1, 3, and 6 months
into the investigation, plus weekly assessment of corneal clarity and
haze. Determination of haze was made using the grading system of
Hanna.25 The Yates correction for the 2 test for associations was used
to analyze prognostic outcomes.26 The animals were killed at 6
months, and histopathologic sections were prepared, to assess the
epithelial and stromal thickness, cell density, and cell characterization.
RESULTS
For comparison purposes, the range of haze grading assess-
ments for the rabbits in each of the groups is summarized in
TABLE 1. Haze Grading and Time Progression at 1, 3, and 6 Month Follow-up Examinations after PRK
Name Pregnant Eyes (n) Tear Sampling 1 mo 3 mo 6 mo
Aprotinin-treated No 2 Yes  2 2
Aprotinin-treated Yes 1 Yes  2 3
Aprotinin-untreated control (contralateral eyes) No 2 Yes   
Aprotinin-untreated control (contralateral eyes) Yes 1 Yes 2 2 2
Non-surgical control No 6 Yes NA NA NA
uPA-treated No 16 No   
uPA-treated Yes 8 No   
uPA-untreated control (contralateral eyes) No 14 No   
uPA-untreated control (contralateral eyes) No 2 No  1–2 1–0
uPA-untreated control (contralateral eyes) Yes 1 No   
uPA-untreated control (contralateral eyes) Yes 7 No  1–2 0.5–1
, Clear corneas; , trace of haze; NA, not applicable.
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Table 1 corresponding to 1-, 3-, and 6-month follow-up exam-
inations.
The time course of measured uPA activities is shown in
Figure 1 for the aprotinin-treated, aprotinin-untreated control,
and nonsurgical control eyes. Aprotinin inhibited uPA activity
in the aprotinin-treated eyes over the 7 days of aprotinin
administration. Two aprotinin-treated eyes (one from the preg-
nant rabbit) showed development of grade-2 haze by the third
month and remained at this haze grade through the 6-month
follow-up period. The third aprotinin-treated eye showed
grade-2 haze by the third month, progressed to grade 3 by the
fourth month, and remained at that level through month 6.
Two of the aprotinin-untreated control eyes exhibited the
expected normal uPA activity, shown in Figure 1, decreasing
immediately after surgery, rising to an elevated level on the day
after surgery, and then returning to presurgical values. The
corneas of these two eyes remained clear (haze free) during the
follow-up. The remaining aprotinin-untreated control eye fol-
lowed a different pattern, shown in Figure 1, where the uPA
activity declined immediately after surgery and remained low
for several days after surgery until finally returning to presur-
gical values after almost 2 weeks. In this rabbit grade-2 haze
developed by the first month and remained at grade 2 over the
6-month follow-up (the contralateral aprotinin-treated eye had
grade-2 haze by month 3, remaining through month 6). This
rabbit was pregnant. The nonsurgical control rabbit eyes un-
derwent no surgery or aprotinin treatment and displayed es-
sentially level uPA activities over the observation period, as
shown in Figure 1.
As indicated in Table 1, there were clear corneas in 24 of 24
uPA-treated eyes (8 of the 24 were in pregnant rabbits) and in
15 of 24 uPA-untreated eyes (1 of the 15 was in a pregnant
rabbit). Post-PRK haze (maximum of grade 1 to 2 at 3 months)
formed in 9 of 24 uPA-untreated eyes (seven of the nine haze
observations were in pregnant rabbits). Within the pregnant
rabbit group, six eyes showed the appearance of haze by the
first month, progressing to grade-2 haze by the third month,
and receding to haze grade 0.5 to 1.0 by month 6. An additional
pregnant rabbit began showing haze by the first month, pro-
gressed to grade 1.0 by month 3, and remained at that level
through month 6. Regarding the two nonpregnant rabbits,
haze also began to appear by the first month. One animal
progressed to haze grade 2 by month 3 and receded to 0 by
month 6, and the other progressed to haze grade 1 by month
3 and remained at that level through month 6. Epithelial inter-
face debris but no haze was observed in 1 uPA-treated eye and
in 1 uPA-untreated eye (neither rabbit was pregnant).
A summary of the post-PRK corneal conditions during the
follow-up period is presented in Table 2 for both uPA-treated
and -untreated groups, separately accounting for pregnant and
nonpregnant rabbits. None of the uPA-treated eyes had haze,
whereas haze developed in 38% of the contralateral uPA-un-
treated eyes. The results in Table 2 show a strong association
between the use of uPA treatment and clear corneas (P 
0.003). In the uPA experiments, 7 of 8 pregnant rabbits versus
2 of 16 nonpregnant rabbits had haze. This represents a strong
association between pregnancy and haze (P  0.002). More-
over, these outcomes show an odds ratio26 of 49 to 1 that
pregnant rabbits had a greater tendency toward development
of haze than nonpregnant rabbits.
The histopathologic sections revealed no difference be-
tween the uPA-treated and non–uPA-treated groups with re-
spect to epithelial thickness, stromal thickness, and cell den-
sity. The character of basal epithelial cells and activated
fibrocytes in the anterior stroma were indistinguishable be-
tween the uPA- and non–uPA-treated clear corneas (no haze).
Among the non–uPA-treated eyes that had haze, more dark
basal epithelial cells were identified, with a larger number of
activated fibrocytes in the anterior stroma.
DISCUSSION
Previous analyses of rabbit tears have revealed uPA activity
levels of 2.0  0.6 IU/mL27 and 4.0  2.5 IU/mL24 in the
preoperative, normal, healthy animal. The equilibrium uPA
activity levels in the present experiments were close to that
range (approximately 3 IU/mL) as seen in Figure 1.
FIGURE 1. Time course of uPA activ-
ity measured in rabbit tears relative
to PRK: three aprotinin-treated eyes
(dashed curves), two nonpregnant
aprotinin-untreated control eyes
(light solid curves), one pregnant
aprotinin-untreated eye (heavy solid
curve), and six nonsurgical control
eyes (dotted curves).
TABLE 2. Number of Pregnant and Nonpregnant Rabbits Having Haze
or Clear Post-PRK Corneal Conditions and Percentage of All Eyes in
the uPA-Treated and uPA-Untreated Groups
8 Pregnant
16
Nonpregnant 24 Total
Haze Clear Haze Clear Haze Clear
uPA-Treated 0 8 0 16 0% 100%
uPA-Untreated
control
(contralateral
Eyes) 7 1 2 14 38% 62%
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Interface debris has been found as an early postoperative
complication after laser refractive surgery.28 In the present
study, epithelial interface debris was seen in both a uPA-
untreated eye and a uPA-treated eye (in animals neither preg-
nant nor showing haze). The occurrence of interface debris in
2 of 54 of the surgical eyes in this study is interpreted to be
independent of the uPA treatment.
Various substances have been considered as agents for the
treatment of corneal haze, including steroids, nonsteroidal anti-
inflammatory drugs, growth factors, basement membrane com-
ponents, regulators of collagen structure, aldose reductase in-
hibitors, antioxidants, immunomodulators, antiallergics, and
antimicrobials.29 For instance, the synthetic inhibitor of met-
alloproteinase was reported to reduce corneal haze in rabbits
by controlling the synthesis of type III collagen30 and to reduce
scar deposition in a rabbit model during glaucoma filtration
surgery.31 The topical application of -methasone (a cortico-
steroid), acting as an antiinflammatory agent, decreased haze
formation in rabbits but did not eliminate it.32 Mitomycin C, an
alkylating agent with antineoplastic and antibiotic activities,
has been reported to reduce haze after PRK by suppressing
keratocyte proliferation.33–35 Elevated levels of transforming
growth factor (TGF)- have been found to correlate with stro-
mal haze formation in humans,36 rabbits,37,38 and rats.39 Top-
ical interferon- 2b in conjunction with dexamethasone, an
adrenocortical steroid, reduces haze in rabbits,40 but used
alone in humans, interferon- 2b appears to have a short-term
benefit in patients who undergo a correction of 5.0 D or
greater.41 Hydrocortisone acetate with vitamin E was shown to
reduce the wound-healing response in rabbits after PRK.42
The natural depression of uPA in the pregnant rabbit (Fig. 1)
and the artificial inhibition of uPA activity in the aprotinin-
treated eyes (Fig. 1 and Csutak et al.17) correlate with the
occurrence of corneal haze after PRK. The pattern of de-
pressed uPA activity in these eyes for several days after PRK
mimics that in human eyes in which haze develops after PRK.5
In contrast, post-PRK clear corneas follow a pattern of elevated
uPA activity over that same period (Fig. 1 and Csutak et al.5,17).
These experiments suggest a significant role for uPA in the
post-PRK wound-healing process relative to haze formation.
The biochemical cascades leading to both tissue destruction
and repair are triggered by uPA, which is responsible for the
activation through proteolytic cleavage of plasminogen to plas-
min. Plasmin degrades fibronectin and laminin in the extracel-
lular matrix, facilitating cell sliding and healing. Plasmin also
activates latent procollagenase to collagenase, resulting in col-
lagen molecule degradation, and participates in feedback to
fibroblast cells inducing them to secrete more uPA.43–45 How-
ever, uPA has been shown to have no direct effect on glyco-
protein and collagen in basement membrane.46 The influence
of the plasminogen-plasmin-fibronectin-laminin-collagenase
cascade on the wound-healing process is governed by the uPA
available to initiate and continue these processes. The imme-
diate conclusion is to provide uPA in the form of eye drops in
situations in which a deficiency of uPA might otherwise lead to
haze.
In the present uPA experiments, the uPA was administered
at a concentration of 50 IU/mL, with a dosage of 1 drop per
hour on day 1 and 1 drop every 2 hours on days 2 to 5. The
intention was to use a higher than normal dosage, but well
within a safe level. Doses as high as 2500 IU/mL have been
shown to be nontoxic to the cornea in vitro.14 Other experi-
ments showed no meaningful swelling of rabbit corneas after
in vitro perfusion of endothelium with uPA at concentrations
of 1000, 2500, and 5000 IU/mL for 3 hours.47 After these
perfusions, scanning electron microscopy demonstrated nor-
mal endothelial mosaic.47 Extrapolation of the rabbit data to
humans led to the conclusion47 that uPA could be used safely
at concentrations of 2500 IU/mL to irrigate hyphemas from the
anterior chamber of the eye without causing direct corneal
damage. With this background, the concentration of uPA cho-
sen in this study for therapeutic or prophylactic use appears to
be reasonable.
The present results suggest that pregnancy is a risk factor
for post-PRK haze in uPA-untreated rabbit eyes. For this reason,
the pregnant rabbit is a useful animal model in which to assess
the efficacy of haze-reduction therapies and procedures after
PRK, without having to resort to extremely deep ablation
depths to produce haze.
The absence of haze in the corneas of the uPA-treated
group, whereas 38% of the uPA-untreated contralateral eyes
had haze, suggests that uPA is effective in reducing the inci-
dence of haze after PRK. In our previous work, we observed
that uPA deficiency in the first few days after PRK surgery
correlates with the development of haze in humans5 and rab-
bits.17 In the present work, we observed that administering
uPA over the first few days after PRK to rabbits (pregnant) that
are prone to haze correlated with absence of haze.
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